BR112021024020A2 - Ensaio de vetor viral de precisão ultra-alta - Google Patents
Ensaio de vetor viral de precisão ultra-altaInfo
- Publication number
- BR112021024020A2 BR112021024020A2 BR112021024020A BR112021024020A BR112021024020A2 BR 112021024020 A2 BR112021024020 A2 BR 112021024020A2 BR 112021024020 A BR112021024020 A BR 112021024020A BR 112021024020 A BR112021024020 A BR 112021024020A BR 112021024020 A2 BR112021024020 A2 BR 112021024020A2
- Authority
- BR
- Brazil
- Prior art keywords
- viral vector
- assay
- cells
- ultra
- replication
- Prior art date
Links
- 238000003556 assay Methods 0.000 title abstract 4
- 239000013603 viral vector Substances 0.000 title abstract 4
- 238000013459 approach Methods 0.000 abstract 2
- 238000001415 gene therapy Methods 0.000 abstract 2
- 230000010076 replication Effects 0.000 abstract 2
- 241001068263 Replication competent viruses Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000006166 lysate Substances 0.000 abstract 1
- 230000002934 lysing effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000002463 transducing effect Effects 0.000 abstract 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/113—PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Manufacturing & Machinery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/426,124 US12152281B2 (en) | 2019-05-30 | 2019-05-30 | Gene therapy vector contamination assay |
| PCT/US2020/034146 WO2020242913A1 (en) | 2019-05-30 | 2020-05-22 | Ultra-high-precision viral vector assay |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021024020A2 true BR112021024020A2 (pt) | 2022-04-12 |
Family
ID=67984844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021024020A BR112021024020A2 (pt) | 2019-05-30 | 2020-05-22 | Ensaio de vetor viral de precisão ultra-alta |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12152281B2 (https=) |
| EP (1) | EP3976803A4 (https=) |
| JP (2) | JP7755490B2 (https=) |
| KR (1) | KR20220016071A (https=) |
| CN (1) | CN113874514A (https=) |
| AU (1) | AU2020283526A1 (https=) |
| BR (1) | BR112021024020A2 (https=) |
| CA (1) | CA3140145A1 (https=) |
| IL (1) | IL288404B2 (https=) |
| WO (1) | WO2020242913A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12152281B2 (en) | 2019-05-30 | 2024-11-26 | Trizell Ltd. | Gene therapy vector contamination assay |
| CN111041131B (zh) * | 2020-03-16 | 2020-07-10 | 广东永诺医疗科技有限公司 | 基于微滴式数字pcr的eb病毒检测试剂盒 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410010B1 (en) * | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
| EP1238091A2 (en) * | 1999-12-14 | 2002-09-11 | Genovo, Incorporated | Methods and compositions for the manufacture of replication incompetent adenovirus |
| WO2003104476A2 (en) | 2002-06-07 | 2003-12-18 | Novartis Ag | Assay to detect replication competent viruses |
| US20080193484A1 (en) | 2004-10-25 | 2008-08-14 | Biogen Idec Ma Inc. | Novel Methods for Producing Adenoviral Vector Preparations with Reduced Replication-Competent Adenovirus Contamination and Novel Adenoviral Vectors and Preparations |
| WO2008079354A2 (en) | 2006-12-22 | 2008-07-03 | Schering Corporation | Methods of detecting replication competent adenovirus |
| CN102884196B (zh) | 2010-04-01 | 2015-05-06 | 肖卫东 | 重组病毒载体的结构及其制备 |
| EP3181704B1 (en) * | 2010-12-27 | 2021-01-27 | Abbott Molecular Inc. | Quantitating high titer samples by digital pcr |
| CN102134613B (zh) * | 2010-12-31 | 2013-01-30 | 中国人民解放军第三军医大学 | 重组慢病毒滴度的检测方法 |
| CA2871774C (en) * | 2012-04-26 | 2021-05-18 | Sentient Lifesciences, Inc. | Use of n-acetylcysteine amide in the treatment of disease and injury |
| CA2925942C (en) * | 2013-10-01 | 2022-05-03 | Texcell | Detection of rare microbiological nucleic acids |
| US11193176B2 (en) * | 2013-12-31 | 2021-12-07 | Bio-Rad Laboratories, Inc. | Method for detecting and quantifying latent retroviral RNA species |
| EP3387138B1 (en) | 2015-12-11 | 2022-01-26 | The Trustees Of The University Of Pennsylvania | Scalable purification method for aav9 |
| RS67367B1 (sr) * | 2016-04-14 | 2025-11-28 | Ferring Ventures Ltd | Bioreaktor sa fiksiranim slojem sa pumpom/sistemom creva sa konstantnim protokom |
| GB2549799A (en) * | 2016-04-29 | 2017-11-01 | Nat Univ Ireland Galway | A multiplex assay for the sensitive and specific detection and differentiation of Clostridium difficile |
| JP7483373B2 (ja) * | 2016-07-29 | 2024-05-15 | ジュノー セラピューティクス インコーポレイテッド | 複製可能ウイルスの存在または非存在を評価するための方法 |
| CN107794291A (zh) * | 2017-04-10 | 2018-03-13 | 中山大学 | 一种抗新加坡石斑鱼虹彩病毒的药物筛选方法 |
| CN108570449A (zh) * | 2018-05-17 | 2018-09-25 | 石河子大学 | 一种带有自发性kshv裂解复制的神经元细胞的构建方法 |
| US12152281B2 (en) | 2019-05-30 | 2024-11-26 | Trizell Ltd. | Gene therapy vector contamination assay |
-
2019
- 2019-05-30 US US16/426,124 patent/US12152281B2/en active Active
-
2020
- 2020-05-22 IL IL288404A patent/IL288404B2/en unknown
- 2020-05-22 CN CN202080038925.9A patent/CN113874514A/zh active Pending
- 2020-05-22 JP JP2021569884A patent/JP7755490B2/ja active Active
- 2020-05-22 EP EP20812945.2A patent/EP3976803A4/en active Pending
- 2020-05-22 CA CA3140145A patent/CA3140145A1/en active Pending
- 2020-05-22 AU AU2020283526A patent/AU2020283526A1/en active Pending
- 2020-05-22 BR BR112021024020A patent/BR112021024020A2/pt unknown
- 2020-05-22 WO PCT/US2020/034146 patent/WO2020242913A1/en not_active Ceased
- 2020-05-22 KR KR1020217038299A patent/KR20220016071A/ko active Pending
-
2024
- 2024-11-07 US US18/940,233 patent/US20250163519A1/en active Pending
-
2025
- 2025-06-13 JP JP2025099242A patent/JP2025123368A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020242913A1 (en) | 2020-12-03 |
| AU2020283526A1 (en) | 2021-12-23 |
| JP2022534483A (ja) | 2022-08-01 |
| IL288404B1 (en) | 2024-11-01 |
| CA3140145A1 (en) | 2020-12-03 |
| EP3976803A4 (en) | 2023-11-22 |
| US12152281B2 (en) | 2024-11-26 |
| KR20220016071A (ko) | 2022-02-08 |
| US20250163519A1 (en) | 2025-05-22 |
| IL288404A (en) | 2022-01-01 |
| JP2025123368A (ja) | 2025-08-22 |
| CN113874514A (zh) | 2021-12-31 |
| EP3976803A1 (en) | 2022-04-06 |
| JP7755490B2 (ja) | 2025-10-16 |
| IL288404B2 (en) | 2025-03-01 |
| US20190292609A1 (en) | 2019-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Anfasa et al. | Phenotypic differences between Asian and African lineage Zika viruses in human neural progenitor cells | |
| Lussignol et al. | The herpes simplex virus 1 Us11 protein inhibits autophagy through its interaction with the protein kinase PKR | |
| Pan et al. | Modulation of Kaposi's sarcoma-associated herpesvirus infection and replication by MEK/ERK, JNK, and p38 multiple mitogen-activated protein kinase pathways during primary infection | |
| Wollebo et al. | CRISPR/Cas9 system as an agent for eliminating polyomavirus JC infection | |
| Malouli et al. | Cytomegaloviral determinants of CD8+ T cell programming and RhCMV/SIV vaccine efficacy | |
| Fu et al. | MicroRNA miR-21 attenuates human cytomegalovirus replication in neural cells by targeting Cdc25a | |
| Xie et al. | Human cytomegalovirus exploits interferon-induced transmembrane proteins to facilitate morphogenesis of the virion assembly compartment | |
| Botto et al. | Human cytomegalovirus immediate early 86-kDa protein blocks transcription and induces degradation of the immature interleukin-1β protein during virion-mediated activation of the AIM2 inflammasome | |
| Pavlova et al. | Disruption of gammaherpesvirus 68 gene 50 demonstrates that Rta is essential for virus replication | |
| Baylis et al. | Analysis of porcine circovirus type 1 detected in Rotarix vaccine | |
| Ayllon et al. | Strain-specific contribution of NS1-activated phosphoinositide 3-kinase signaling to influenza A virus replication and virulence | |
| Krump et al. | Merkel cell polyomavirus infection induces an antiviral innate immune response in human dermal fibroblasts | |
| BR112021024020A2 (pt) | Ensaio de vetor viral de precisão ultra-alta | |
| Vincent et al. | Mechanism of protein kinase R inhibition by human cytomegalovirus pTRS1 | |
| Oyaizu et al. | Complementation of the function of glycoprotein H of human herpesvirus 6 variant A by glycoprotein H of variant B in the virus life cycle | |
| Nukui et al. | Protein S-nitrosylation of human cytomegalovirus pp71 inhibits its ability to limit STING antiviral responses | |
| Battivelli et al. | Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to human TRIM5α, linking intrinsic and acquired immunity | |
| Zimmermann et al. | The abundant tegument protein pUL25 of human cytomegalovirus prevents proteasomal degradation of pUL26 and supports its suppression of ISGylation | |
| Habison et al. | Cross-species conservation of episome maintenance provides a basis for in vivo investigation of Kaposi's sarcoma herpesvirus LANA | |
| Kurtz et al. | Equus caballus major histocompatibility complex class I is an entry receptor for equine herpesvirus type 1 | |
| Zheng et al. | An A14U substitution in the 3′ noncoding region of the M segment of viral RNA supports replication of influenza virus with an NS1 deletion by modulating alternative splicing of M segment mRNAs | |
| Olson et al. | Deletion of the vaccinia virus B1 kinase reveals essential functions of this enzyme complemented partly by the homologous cellular kinase VRK2 | |
| Ismail et al. | Selection pressure in the human adenovirus fiber knob drives cell specificity in epidemic keratoconjunctivitis | |
| BR0007690A (pt) | Célula recombinante, kit, e, métodos para detectar a presença de vìrus hiv e de diferentes cepas de vìrus hiv em uma amostra, para detectar resistência do hiv à droga em uma amostra, para tomar um paciente que se sabe estar infectado com uma ou mais cepas do vìrus hiv e determinar qual combinação de um ou mais agentes anti-hiv poderia ser efetiva no tratamento do paciente e para triar composições quanto à atividade anti-hiv | |
| El-Mayet et al. | Synergistic activation of bovine herpesvirus 1 productive infection and viral regulatory promoters by the progesterone receptor and Krüppel-like transcription factor 15 |